A phenome-wide association study of a lipoprotein-associated phospholipase A2 loss-of-function variant in 90 000 Chinese adults

International Journal of Epidemiology

Volumn 45, Issue 5, 2016, Pages 1588-1599

  Millwood, Iona Y ^a,g   Bennett, Derrick A ^a,g   Walters, Robin G ^a,g   Clarke, Robert ^a,g   Waterworth, Dawn ^b,c   Johnson, Toby ^b,c   Chen, Yiping ^a,g   Yang, Ling ^a,g   Guo, Yu ^d   Bian, Zheng ^d,h   Hacker, Alex ^a,g   Yeo, Astrid ^b,c   Parish, Sarah ^a   Hill, Michael R ^a,g   Chissoe, Stephanie ^b,c   Peto, Richard ^a,f   Cardon, Lon ^b,c   Collins, Rory ^a,f   Li, Liming ^d,e,f   Chen, Zhengming ^a,f,g   Chen, Junshi ^f   Avery, Daniel ^g   Chang, Yumei ^g   Du, Huaidong ^g   Fan, Xuejuan ^g   Gilbert, Simon ^g   Holmes, Michael ^g   Iona, Andri ^g   Kerosi, Rene ^g   Kong, Ling ^g   Kurmi, Om ^g   Lancaster, Garry ^g   Lewington, Sarah ^g   McDonnell, John ^g   Mei, Winnie ^g   Nie, Qunhua ^g   Radhakrishnan, Jayakrishnan ^g   Ryder, Paul ^g   Sansome, Sam ^g   Schmidt, Dan ^g   Sherliker, Paul ^g   Sohoni, Rajani ^g   Sun, Luanlaun ^g   Wang, Jenny ^g   Wang, Lin ^g   Yang, Xiaoming ^g   Chen, Ge ^h   Guo, Lei ^h   Han, Bingyang ^h   Hou, Can ^h   Liu, Peng ^h   Lv, Jun ^h   Pei, Pei ^h   Qu, Shuzhen ^h   Tan, Yunlong ^h   Yu, Canqing ^h   Zhou, Huiyan ^h   Pang, Zengchang ^f,i   Wang, Shaojie ^f,i   Zhang, Yun ^f,i   Zhang, Kui ^f,i   Liu, Silu ^f   Hou, Wei ^f   Zhao, Zhonghou ^f   Liu, Shumei ^f   Pang, Zhigang ^f   Feng, Weijia ^f   Wu, Shuling ^f   Yang, Liqiu ^f   Han, Huili ^f   He, Hui ^f   Yu, Bo ^f   Pan, Xianhai ^f   Wang, Shanqing ^f   Wang, Hongmei ^f   Hao, Xinhua ^f   Chen, Chunxing ^f   Lin, Shuxiong ^f   Zheng, Xiangyang ^f   Hu, Xiaoshu ^f   Zhou, Minghao ^f   Wu, Ming ^f   Tao, Ran ^f   Wang, Yeyuan ^f   Hu, Yihe ^f   Ma, Liangcai ^f   Zhou, Renxian ^f   Xu, Guanqun ^f   Lu, Yan ^f   Dong, Baiqing ^f   Chen, Naying ^f   Huang, Ying ^f   Li, Mingqiang ^f   Meng, Jinhuai ^f   Gan, Zhigao ^f   Xu, Jiujiu ^f   Liu, Yun ^f   Qing, Jingxin ^f   Wu, Xianping ^f   Gao, Yali ^f   Zhang, Ningmei ^f   Luo, Guojin ^f   Que, Xiangsan ^f   Chen, Xiaofang ^f   Ge, Pengfei ^f   He, Jian ^f   Ren, Xiaolan ^f   Zhang, Hui ^f   Mao, Enke ^f   Li, Guanzhong ^f   Li, Zhongxiao ^f   He, Jun ^f   Lei, Yulong ^f   Wang, Xiaoping ^f   Liu, Guohua ^f   Zhu, Baoyu ^f   Zhou, Gang ^f   Feng, Shixian ^f   Gao, Yulian ^f   He, Tianyou ^f   Jiang, Li ^f   Qin, Jianhua ^f   Sun, Huarong ^f   Liu, Liqun ^f   Yu, Min ^f   Chen, Yaping ^f   Hu, Ruying ^f   Hu, Zhixiang ^f   Hu, Jianjin ^f   Qian, Yijian ^f   Wu, Zhiying ^f   Wang, Chunmei ^f   Chen, Lingli ^f   Liu, Wen ^f   Li, Guangchun ^f   Liu, Huilin ^f   Long, Xiangquan ^f   Xu, Xin ^f   Xiong, Youping ^f   Tan, Zhongwen ^f   Xie, Xuqiu ^f   Peng, Yunfang ^f   Jia, Weifang ^f   Chao, Nie ^j   Jun, Wang ^j   Li, Qibin ^j   Liu, Xiao ^j   Zhou, Hongcheng ^j   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c GLAXOSMITHKLINE   (United States)

^d PEKING UNION MEDICAL COLLEGE   (China)

^e PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^f International Coordinating Centre ^*  (China)

^g International Coordinating Centre   (United Kingdom)

^h China Ordins Corporation   (China)

ⁱ Ten Regional Co ordinating Centres   (China)

^j BGI Tech BGI Shenzhen   (China)

more..

Author keywords

China; Genetic association; Lp PLA2; Phenome wide; Vascular disease

Indexed keywords

GLUCOSE; LIPOPROTEIN; PHOSPHOLIPASE A2; 1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; PLA2G7 PROTEIN, HUMAN;

ADULT; ANTHROPOMETRY; ARTICLE; BLOOD PRESSURE; CEREBROVASCULAR ACCIDENT; CHINA; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC TEST ACCURACY STUDY; DRUG REPOSITIONING; FEMALE; FOLLOW UP; GENE; GENETIC VARIABILITY; GENOTYPE; GLUCOSE BLOOD LEVEL; HETEROZYGOSITY; HUMAN; ICD-10; LOSS OF FUNCTION MUTATION; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBESITY; PLA2G7 GENE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; VASCULAR DISEASE; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION; GENETICS; INTERNATIONAL CLASSIFICATION OF DISEASES; METABOLISM; PHENOTYPE; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL MODEL;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTERNATIONAL CLASSIFICATION OF DISEASES; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RISK FACTORS; VASCULAR DISEASES;

EID: 85020565329     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyw087     Document Type: Article

References (36)

1. Kolodgie FD, Burke AP, Skorija KS et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2006;26:2523–29.
2. Stafforini DM. Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2). Cardiovasc Drugs Ther 2009;23:73–83.
3. Tjoelker LW, Wilder C, Eberhardt C et al. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 1995;374:549–53.
4. Rosenson RS, Stafforini DM. Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2. J Lipid Res 2012;53:1767–82.
5. Mohler ER 3rd, Ballantyne CM, Davidson MH et al. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2008;51:1632–41.
6. White HD, Held C, Stewart R et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med 2014;370:1702–11.
7. O’Donoghue ML, Braunwald E, White HD et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA 2014;312:1006–15.
8. Thompson A, Gao P, Orfei L et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010;375:1536–44.
9. Heart Protection Study Collaborative G. Lipoprotein-associated phospholipase A(2) activity and mass in relation to vascular disease and nonvascular mortality. J Intern Med 2010;268:348–58.
10. Evans DM, Davey Smith G. Mendelian randomization: new applications in the coming age of hypothesis-free causality. Annu Rev Genomics Hum Genet 2015;16:327–50.
11. Stafforini DM, Satoh K, Atkinson DL et al. Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase. J Clin Invest 1996;97:2784–91.
12. Zhang SY, Shibata H, Karino K et al. Comprehensive evaluation of genetic and environmental factors influencing the plasma lipoprotein-associated phospholipase A2 activity in a Japanese population. Hypertens Res 2007;30:403–09.
13. Hou L, Chen S, Yu H et al. Associations of PLA2G7 gene polymorphisms with plasma lipoprotein-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population: the Beijing atherosclerosis study. Hum Genet 2009;125:11–20.
14. Balta G, Gurgey A, Kudayarov DK, Tunc B, Altay C. Evidence for the existence of the PAF acetylhydrolase mutation (Val279Phe) in non-Japanese populations: a preliminary study in Turkey, Azerbaijan, and Kyrgyzstan. Thromb Res 2001;101:231–34.
15. Yamada Y, Yoshida H, Ichihara S, Imaizumi T, Satoh K, Yokota M. Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population. Atherosclerosis 2000;150:209–16.
16. Wang Q, Hao Y, Mo X et al. PLA2G7 gene polymorphisms and coronary heart disease risk: a meta-analysis. Thromb Res 2010;126:498–503.
17. Zheng GH, Chen HY, Xiong SQ, Chu JF. Lipoprotein-associated phospholipase A2 gene V279F polymorphisms and coronary heart disease: a meta-analysis. Mol Biol Rep 2011;38:4089–99.
18. Jang Y, Waterworth D, Lee JE et al. Carriage of the V279F null allele within the gene encoding Lp-PLA(2) is protective from coronary artery disease in South Korean males. PLoS One 2011;6:e18208.
19. Millwood IY, Bennett DA, Walters RG et al. Lipoprotein-associated phospholipase A2 loss-of-function variant and risk of vascular diseases in 90,000 Chinese adults. J Am Coll Cardiol 2016;67:230–31.
20. Chen Z, Chen J, Collins R et al. China Kadoorie Biobank of 0.5 million people: survey methods, baseline characteristics and long-term follow-up. Int J Epidemiol 2011;40:1652–66.
21. Chen Z, Lee L, Chen J et al. Cohort Profile: The Kadoorie Study of Chronic Disease in China (KSCDC). Int J Epidemiol 2005;34:1243–49.
22. Bragg F, Li L, Smith M et al. Associations of blood glucose and prevalent diabetes with risk of cardiovascular disease in 500 000 adult Chinese: the China Kadoorie Biobank. Diabet Med 2014;31:540–51.
23. Kurmi OP, Li L, Smith M et al. Regional variations in the prevalence and misdiagnosis of air flow obstruction in China: baseline results from a prospective cohort of the China Kadoorie Biobank (CKB). BMJ Open Respir Res 2014;1:e000025.
24. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:1322.
25. Yamada Y, Matsuo H, Segawa T et al. Assessment of genetic risk for myocardial infarction. Thromb Haemost 2006;96:220–27.
26. Shimokata K, Yamada Y, Kondo T et al. Association of gene polymorphisms with coronary artery disease in individuals with or without nonfamilial hypercholesterolemia. Atherosclerosis 2004;172:167–73.
27. Hiramoto M, Yoshida H, Imaizumi T, Yoshimizu N, Satoh K. A mutation in plasma platelet-activating factor acetylhydrolase (Val279–> Phe) is a genetic risk factor for stroke. Stroke 1997;28:2417–20.
28. Yoshida H, Imaizumi T, Fujimoto K et al. A mutation in plasma platelet-activating factor acetylhydrolase (Val279Phe) is a genetic risk factor for cerebral hemorrhage but not for hypertension. Thromb Haemost 1998;80:372–75.
29. Liu X, Zhu RX, Tian YL et al. Association of PLA2G7 gene polymorphisms with ischemic stroke in northern Chinese Han population. Clin Biochem 2014;47:404–08.
30. Casas JP, Ninio E, Panayiotou A et al. PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European ancestry. Circulation 2010;121:2284–93.
31. Polfus LM, Gibbs RA, Boerwinkle E. Coronary heart disease and genetic variants with low phospholipase A activity. N Engl J Med 2015;372:295–96.
32. Ference BA, Yoo W, Alesh I et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol 2012;60:2631–39.
33. White H, Held C, Stewart R et al. Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease. Am Heart J 2010;160:655–61.
34. Sofat R, Hingorani AD, Smeeth L et al. Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms. Circulation 2010;121:52–62.
35. Davey Smith G, Timpson N, Ebrahim S. Strengthening causal inference in cardiovascular epidemiology through Mendelian randomization. Ann Med 2008;40:524–41.
36. Sudlow C, Gallacher J, Allen N et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med 2015; 12:e1001779.